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The  eye has  received  considerable  attention  in  the  study  and  evaluation  of
the  effect  of  interferon  and  interferon  inducers  on  viral  disease.  Since  this
organ is easily visualized,  permits easy access to culture material,  is frequently
involved  in viral  infections,  and can  be studied  under intense  magnification
in the in vivo state, it is a logical  organ system for such study.  Furthermore,
most ocular diseases  can be treated topically,  and the effects of therapy  with
interferon  and/or  interferon  inducers  may  be  studied  without  some  of the
problems  encountered  in  evaluating  the  influence  of  systemic  therapy  on
local organ disease.
In  1960,  Cantell  and  Tommila reported  on  the effects of exogenous  inter-
feron  on  vaccinia  keratitis.  They  noted  that  the  external  application  of
interferon,  derived  from  rabbit kidney  cells,  to  rabbit  eyes  for  4  days  after
corneal  inoculation  of vaccinia  virus  delayed  and  suppressed  the  signs  of
infection  (1).  These  same  investigators  also  noted  that  a  similar  course  of
treatment did not  influence  herpes simplex virus  infection  of rabbit corneas.
Jones  et  al.  treated  five  cases  of  human  epithelial  vaccinia keratitis  with
topical  monkey  interferon  applied  every  12  hr during  the  patient's  waking
hours  (2).  They  noted  that  topical  interferon  appeared  to  have  a specific
antiviral  effect  on the epithelial  stages of the disease,  and  that if stromal in-
volvement  had  occurred,  these  changes  were  not  altered.  Rapid  healing  of
the  epithelial  infection  was noted,  and  it was  clear  that in no  instance  was
there  worsening  of  the  epithelial  lesions  once  interferon  was  administered.
Tommila  and  Penttinen  attempted  to  determine  why  herpes  simplex
viruses had proved to be relatively  insensitive to interferon  applied to rabbit
eyes  in vivo as well  as in tissue culture (3).  They reasoned that the failure  of
exogenously  applied  interferon  might  be due  to  the  low  interferon  content
of the  administered  material,  as  well  as  to  insufficient  application  of  the
preparation  used.  They  endeavored  to  produce  a  high  interferon  concen-
tration in the eye by applying  the virus that had been  utilized in the  prepa-
ration  of interferon  in  vitro  directly  to  the  eye.  A  study was  undertaken,
therefore,  to  determine  the  effect  of ultraviolet  irradiated  influenza  type  B,
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strain  Lee  (E  158),  on experimental  herpes  simplex  virus infection  of rabbit
cornea.  These  investigators  found  that  this inactivated virus was capable  of
reducing the severity  of herpes infection if therapy was initiated the day after
viral  inoculation.  If,  however,  the  same  therapy was  instituted  4 days  after
the  rabbits  had  been  infected,  the  inducing  virus  had  no  influence  on  the
severity  of the ocular  infection.
Tommila  continued  his  investigations  utilizing  irradiated  influenza  type
B virus  of the Lee  strain  as  an  interferon  inducer  by  employing  interferon
prepared in primary human amniotic cell culture in the treatment of dendritic
keratitis in patients  (4). He reasoned that direct interferon  application  might
be effective in patients against herpes simplex, while it is ineffective in rabbits,
because  of the  less  stormy course  this disease  took  in humans.  Furthermore,
it would obviously be easier  to assess quantitative  administration  in patients.
Two drops  of the interferon  preparation  were  administered  every  other hour
until  healing  began and then  every  3 hr. Control  patients were treated  with
iodine cauterization.  It  was the author's impression  that recovery had started
and that corneal  ulcers  had  epithelialized  in  the interferon-treated  group in
half the time required by the control  group. He further noted that interferon
therapy was well  tolerated  and caused  no demonstrable  toxic  changes in the
eye.  It was of significance  in this  investigation that if interferon  therapy was
discontinued  immediately  after  remission  of the  dendritic  form  of keratitis,
the disease  promptly recurred in several cases.
Following  the  investigations  of  Ho,  who  demonstrated  an  interferon-
like inhibitor in the serum of rabbits that had been inoculated with endotoxin
or with  killed  cells  of Escherichia coli,  Oh  and  Gill  demonstrated  that  high
titers of interferon-like  viral inhibitor could  be detected in rabbit  serum and
aqueous  humor  if  the  animals  were  given  intravenous  typhoid  endotoxin
(5,  6).  A  state  of resistance  to  the toxic  corneal  effect  of Newcastle  disease
virus was induced  if 10 or  100  tg of typhoid  endotoxin were given to rabbits
intravenously.  This  favorable  influence  on  corneal  resistance  correlated
well  with the titer of an interferon-like  viral inhibitor in the aqueous humor.
This view was further strengthened  by the finding  that pretreatment of eyes
subjected  to Newcastle  disease virus  by serum or aqueous  humor containing
the  inhibitor  suppressed  the  production  of  the  corneal  opacity  normally
induced  by the infecting virus.
Oh  and  Gill  suggested  that  the mechanism  by which  typhoid  endotoxin
induced corneal resistance to virus involved at least two steps: the intravenous
injection of endotoxin induced an interferon-like viral inhibitor in blood,  and
endotoxin disrupted the blood aqueous barrier of the eye to permit the escape
of the viral inhibitor from the blood into the anterior chamber where it could
act on the corneal  target cells and modify the effect  of the Newcastle  disease
virus.
250  sInvited Discussion
Pollikoff et al.  extended  these previous  studies  by evaluating  the  effect  of
direct corneal  or vitreal injections  of bacterial endotoxin  on corneas scarified
with herpes  simplex virus  (7).  Though a single intravitreous  dose of purified
endotoxin  produced  ocular  inflammation,  if  this  therapy  was  administered
18 hr prior to corneal infection with herpes simplex virus, the development  of
herpetic keratitis  was significantly  reduced.  Assays  of corneas  harvested  48-
192  hr after  infection  showed  a  1-1.7  log  lower  infectivity  titer  in  endo-
toxin treated  eyes than  in  untreated  controls.  Similar results  were  obtained
when the endotoxin was injected intracorneally,  but subconjunctival adminis-
tration  failed  to  induce  resistance.  A marginal  but  significant  therapeutic
effect was also achieved when a single dose of endotoxin  was administered  in-
travitreally  72 hr postinfection.
These data suggested  to the authors that the infectious process might  have
been inhibited  and recovery  accelerated,  as a result of locally induced  inter-
feron-like inhibitor protection  of uninfected cells adjacent to or at the margins
of foci  of  corneal  infection.  These  investigators  further  demonstrated  that
interferon-like  activity  was  detected  in  the  iris  and  ciliary  body  at  3  and
18  hr after  injection  of endotoxin,  whereas  the presence of the inhibitor was
not  demonstrated  at  any  time  in  aqueous  humor,  conjunctiva,  or  cornea.
They  also  noted  that  intravenous  injection  of endotoxin  prior  to  corneal
infection  with  herpes  simplex failed  to  prevent  the development  of herpetic
keratitis,  despite the induction of a significant  level of circulating  interferon.
It  was  their conclusion  that circulating  interferon  did not reach the corneal
epithelium in order to produce a resistant state,  as was  suggted  by  Oh and
Gill for  the induction  of corneal  resistance  to  Newcastle  disease virus.  They
further  hypothesized  that  more  local  rather  than  systemic  production  of
interferon was necessary to restrict the progress  of herpetic keratitis.
Oh and Yoneda shed more light on this subject by evaluating the induction
of ocular resistance  to vaccinia  virus through the use of intravenous typhoid
vaccine  (8).  These investigators noted that the injection of live vaccinia virus
into the anterior chambers of rabbits induced  corneal opacities, characteristic
microscopic  lesions  of the  corneal  endothelium  and  uveitis.  These  changes
were  accompanied  by  an  increase  in  the amount  of virus in both  aqueous
humor  and ocular  tissues.  However,  single intravenous  injections  of  1 ml  of
typhoid  vaccine,  3,  6, or  10 hr prior  to virus  infection  suppressed  both the
production  of the ocular lesions and virus multiplication.  If the inoculum of
vaccinia  was small,  the single intravenous  injection  of typhoid vaccine  could
suppress  ocular infection  up  to 7  days.  If a large  inoculum  of virus was  in-
jected, the onset of infection was still delayed, though for only 1 day.
Intravenous  injection  of the  typhoid  vaccine  was  followed  within  3  hr
by  the  appearance  of an  interferon-like  viral  inhibitor  in  both  blood  and
aqueous  humor,  and  in  some  cases,  the  interferon-like  substance  persisted
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in  the  aqueous  humor  for  as  long  as  10  hr.  These  authors  concluded  that
typhoid  vaccine  induced  corneal  resistance  to  vaccinia  virus  in  rabbits
through  the systemic  induction  of interferon which  acted locally.
After  several  investigators  had  demonstrated  the  potency  of  double-
stranded RNA interferon inducers, Park and Baron carried out studies to evalu-
ate the effect  of  systemic and  local  polyinosinic-polycytidylic  acid  complex
(In  Cn) therapy  on established  herpes  simplex keratitis  (9).  0.1 ml of In  Cn
(1000  pug/ml)  administered  three  times  daily  was  used  in  topical  therapy.
Treatment,  which  was  initiated  in  various  rabbit  groups  as  early  as  3  hr
after  infection  and  as  late  as 4  days  after  inoculation,  was continued  for  6
days  in  all groups.  These  investigators  found that rabbits  that were  treated
beginning at 3 hr after inoculation and up to 24 hr after inoculation developed
minimal  keratoconjunctivitis,  and  that  corneal  lesions  cleared  by  the  6th
day  of therapy.  Though  rabbits in  which  treatment  was  initiated  2-3 days
after  inoculation  all  developed  moderate  to  severe  keratoconjunctivitis  as
well,  their  corneal  lesions  also  subsided  during  the  4-5  days  of  treatment
with In  Cn. No therapeutic  effect was observed  in rabbits in which treatment
was initiated  4 days  or longer  after viral inoculation.
Studies  utilizing  In  Cn  administered  intravenously  or  directly  into  the
anterior chamber resulted in conclusions similar to those derived  from topical
therapy.  These  investigators  further  observed  that  after  intravenous  ad-
ministration  of In  Cn,  a prompt and high interferon level resulted,  and  that
partial  refractoriness  to  the continued  production  of  circulating  interferon
occurred  after the 6th daily  dose of  1000  g  of In  Cn intravenously.
Subsequent  studies  by Baron  et  al.  indicated  that therapy  of established
rabbit  herpetic keratoconjunctivitis  was far more effective  if the viral inocu-
lum was low, and that in all instances,  the  conjunctival  response  was signifi-
cantly  greater  than  the  corneal  response  to  either  topical  or  intravenous
In  Cn.1
A preliminary  study on  the treatment of human  herpetic keratoconjuncti-
vitis with topical  In  Cn has  been reported by Guerra et al.  (10).  These  in-
vestigators  carried  out  a  double-blind  clinical  trial  in  33  patients  suffering
from  clinical  herpes  simplex  keratitis.  21  patients  received  topical  In-Cn,
1000 ,g/ml,  every  10 min during the  1st hr, and one drop hourly thereafter.
12 other patients  were treated with IDU in the standard clinical dose  (0.1%)
administered  as  a  single,  hourly  drop.  Therapy  with  either  method  was
terminated  when  virus  isolation  became  negative.  17  patients  treated  with
In- Cn  and  five  patients  treated  with  IDU  responded  promptly.
Further  investigations  on  rabbit  herpetic  keratoconjunctivitis  indicated
that  topical  or  systemic  administration  of  In .Cn  was  significantly  more
1 Baron, S., J.  Park,  W. Schachter,  M. Weissenbacher,  and M. A.  Galin.  1969.  Personal  communi-
cation.
'25
2Invited Discussion
effective  in  the prevention  of lesions  than  in  the cure  of an  established  in-
fection  (11).  These investigators  found  that  1000  or  100  /ug of intravenously
administered  In-Cn given  3 hr prior to corneal herpes  virus inoculation  and
daily  thereafter  provided  excellent  protection  from  the  development  of
herpetic  keratoconjunctivitis,  whereas  rabbits  receiving  10  or  I  ug  similarly
administered  had  limited  to  poor  protection.  The  level  of circulating  inter-
feron  correlated  well with  the  level  of protection.  The degree  of protection
induced  by  In-Cn  against  herpes  simplex  virus  was  greater  than  that  re-
ported  by other  investigators  who  utilized  systemic  interferon  or endotoxin.
Studies by Schachter et al. further indicated that topical  In  Cn was as effec-
tive  as  IDU  in  the prophylaxis  of  herpetic  keratoconjunctivitis  in  rabbits.2
Kaufman  et  al.  have  recently  reviewed  the  therapeutic  effect  of In.Cn
in experimental  herpes  simplex  keratitis  of rabbits'  eyes  (12).  These  investi-
gators  noted  that  topical  or  systemic  treatment  of acute  corneal  herpetic
lesions  from  two  virus  strains  with  In.Cn  was  far  less  effective  than  with
IDU.  They further  found  that topical  or systemic  treatment  of acute lesions
with  In-Cn  did  not  decrease  the  death rate  from  encephalitis  and did  not
significantly  reduce  the rate of recurrence  of keratitis.  The continued topical
use of In  Cn  provided some protection  to the cornea for 6-8 wk,  but subse-
quently,  the  cornea  appeared  more  susceptible  to  recurrences  of  disease
even though administration  of In  Cn was continued.
Further  substantiation  of  the  observation  that  the  ocular  prophylactic
effect  of  interferon  induction  exceeds  its  therapeutic  effect  was  found  by
Pollikoff et al. during their investigation  of vesicular stomatitis virus on rabbit
eyes  (13).  These investigators  injected a single dose of 38  jug of statalon into
the  vitreous  18  hr prior  to  scarification  of the cornea  with VSV,  and  they
found a  significant reduction  in keratitis  as compared  to controls.  The same
amount  of drug injected  2  hr after virus  scarification,  however,  was  ineffec-
tive.  They  also  evaluated  the  efficacy  of  52  Mig  of In  Cn  in  a  single  intra-
vitreal  dose  2 hr after VSV scarification  of the cornea.  It  was found that this
interferon  inducer  did  not  prevent,  but  significantly  reduced,  the develop-
ment  of keratitis.  Similar  findings  were  obtained  even  when  the  drug was
injected  6  hr postscarification.  Significant  levels of interferon  were detected
in  suspensions  of the cornea,  iris,  and  ciliary body  18  hr  after In.Cn  injec-
tion.  Other routes of administration,  such  as intravenous  or subconjunctival
injection  directly  into  the cornea,  were  equally  effective.  Intracameral  in-
jection,  however,  was ineffective.
Schachter  et  al.  reconfirmed  the  observation  that  herpes  simplex  virus
is relatively resistant to interferon  by evaluating the effect of In  Cn on herpes
2 Schachter,  N., J.  Park,  M. A.  Galin,  S.  Baron,  A.  Billiau,  and  M.  Weissenbacher.  Comparison
of  antiviral  action  of interferon,  interferon  inducers  and  IDU  against  herpes  simplex  and  other
viruses. Submitted for publication.
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simplex virus and VSV in vitro.2 These investigators  evaluated  in rabbit kid-
ney  cells  four pools  of exogenous  interferon  obtained  from rabbit  serum by
intravenous  interferon  induction  utilizing  Sindbis  virus,  polyinosinic  acid-
polycytidylic  acid,  or  In  Cn.  All  of  the  samples  were  less  active  against
herpes  simplex  virus  than  against  VSV,  regardless  of  the  method  of inter-
feron induction.
In  vivo  prophylaxis  experiments  by  these  investigators  compared  the
sensitivity  of  rabbit  cornea  infected  with  herpes  simplex  virus  to  topical
administration  of  pyran  copolymer,  In-Cn,  interferon  itself,  and  IDU.
It was  found that In- Cn and  IDU were  the  only agents  that provided  sig-
nificant protection  against  herpes  simplex  keratoconjunctivitis.  Eyes  treated
with  pyran  copolymer  or  interferon  all  developed  severe  epithelial  and
stromal keratitis with varying  degrees of purulent  conjunctivitis.  The studies
of this  group  indicate  that pyran  copolymer  is  only  effective  systemically,
since the production of interferon by this agent probably is limited to macro-
phages  and  the  reticuloendothelial  system.  Their  studies  also  confirm  the
observation  that  cells  that  produce  interferon  are  more  resistent  to  virus
than  cells  receiving  interferon  from  an  exogenous  source  (14).  This  latter
observation  has clearly  been  demonstrated  as well  in vaccinia  virus infection
of the rabbit eye and in patients suffering from vaccinial keratitis.
Weissenbacher  et  al.  have  studied what  areas  of the rabbit  anterior  seg-
ment  are  capable  of  interferon  production  after  In.Cn stimulation  in  vivo
and  in  vitro.3 They  demonstrated  the  presence  of  interferon  in  aqueous,
vitreous,  and  serum  after  systemic  or intraocular  administration  of In-Cn.
Intravenous  injection  with  o10,  1, or  5  ug  of  In  Cn  induced  measurable
serum  and  aqueous  levels  of  interferon.  Interferon  was  not  detected  in
vitreous  after intravenous  administration  of  o  .ug In.Cn  but was  present
with  higher  doses.  Peak  interferon  levels  were  found  in  all  media  2  hr
after  intravenous  dosage  regardless  of the  level of drug  administered.  Local
injection of In  Cn into the eye did not result in as high a level of intraocular
interferon  as  when  the  equivalent  dose  was  given  intravenously.  The  local
injection  of InC.  n,  however,  prolonged  the  duration  of  interferon  within
the eye.
The  wide range  of studies  alluded  to  in  this  report  clearly  indicate that
ocular  prophylaxis  to  a  variety  of  viruses  may  be  achieved  by systemic  or
topical  administration  of  interferon  inducers.  Further,  the  therapeutic  effi-
cacy of interferon inducers is  significantly less than prophylaxis achieved in a
similar  way.  Furthermore,  it  is  probably  correct  that,  at  least  for  herpes
simplex  virus,  the  conjunctival  response  appears  to  exceed  the corneal  re-
sponse  once  established  infection  has  occurred.  It  also  appears  that  thera-
3 Weissenbacher,  M.,  N. Schachter,  M.  A.  Galin,  and  S.  Baron.  Intraocular  production  of inter-
feron.  Submitted  for  publication.
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peutic  efficacy  is  significantly subject to the concentration  of infective  inocu-
lum.  Since topical administration  of certain interferon  inducers,  particularly
double-stranded  RNA,  is  simple  to  carry  out  and  evaluate,  clinical  trials
utilizing these agents are probably  in order.
This work was aided by Contract No. PH 43-68-1266 from the United States Public Health  Service.
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Discussion from the  Floor
Dr. James G.  Gallagher (University  of Vermont): Dr.  Baron,  I'd like to
comment  on relative  sensitivities  of different viruses  to interferon,  a subject
to which you referred  briefly.  I  am convinced  that there are  indeed  definite
differences  in  sensitivity  to  interferon  among  animal  viruses.  In  order  to
reduce  the  multiplicity  of factors  which  govern  host  defenses  in  the  intact
animal  we  have  examined  adenovirus  sensitivity  to  interferon  in  in  vitro
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systems,  using  both  plaque-reduction  and  yield-inhibition  techniques.  We
have  looked  at  the  sensitivities  of approximately  one-third  of  the  human
adenovirus  serotypes  (types  1-5,  7,  8,  11,  12,  and  18).  The  group  tested
contains viruses with marked differences  in biochemical  and biological prop-
erties  (including  both  tumorigenic  and  nontumorigenic  viruses),  yet  each
exhibits  much less  sensitivity  to interferon  than  do  members  of most  other
animal  virus  groups.  In  comparison  with  the  Indiana  strain  of vesicular
stomatitis virus (VSV),  we find that approximately  125 times as much human
interferon  is required to reduce adenovirus  plaque formation by 50%  than is
required  to  reduce  VSV plaque  counts  by  the  same  amount.'  In  addition,
we have  found vaccinia  virus  to be  less sensitive than VSV to human  inter-
feron,  and this observation  has recently been confirmed.2
We  have  also  looked  at  adenovirus  sensitivity  to  human  interferon  by
quantitative  methods,  i.e.  examining  inhibition  of  adenovirus  yields  from
various  human  diploid  cell  strains  treated  with various  doses  of interferon.
Each  of  the  representative  adenoviruses  tested  (types  2,  7,  and  12)  was
markedly less  sensitive  than was VSV.  At least  100-fold  more human inter-
feron  was  required  to  reduce  adenovirus  yields  by  one-half  logo  unit  or
more  than  was  required  to  effect  similar  reductions  of yields  of  VSV.  In
examining the quantitative  effect of rabbit interferon on adenovirus  multipli-
cation  in  cultured  rabbit  heart  fibroblasts,  we  again  found  a  definite  but
relatively  limited  sensitivity  to the inhibitor.'
Dr. Baron: From your  data it  would  seem  that adenoviruses,  even  at
low  multiplicities  of infection,  are  indeed  more  resistant  than,  as  shown  in
the studies I referred  to  (Catalano and Baron,  1969;  and Easton  et al.,  1969,
personal  communications),  the  herpes  virus  group  and  the  cytomegalovirus
group which become highly  sensitive to interferon with low infective doses in
vivo  and in vitro.  I think in the  adenovirus studies it would be important to
control the effect of decay  of antiviral  resistance  since it usually takes  a long
time for  adenovirus replication.  I'm sure you controlled  this aspect.
Dr.  Gallagher: The  time  required  for  adenovirus  plaque  formation  is,
indeed,  considerably  greater  than that required  for VSV  plaque formation.
To appreciably  reduce  the  time differential  and possible  decay  of the inter-
feron-induced  antiviral  effect, we examined the effect of interferon  on single-
cycle growth of adenoviruses and VSV. All of the yield-inhibition  experiments
described  above were performed  during one-step  growth with adsorbed mul-
tiplicities sufficient  to insure that virtually all of the cells were infected.
Dr. Baron: It  is  true,  however,  that  the  growth  cycle  of adenovirus  is
1Gallagher, J.  G.,  and N. Khoobyarian.  1969.  Adenovirus  susceptibility  to  interferon:  Sensitivity
of Types 2,  7,  and  12 to human interferon.  Proc. Soc. Exp. Biol. Med. 130:  137.
2 Stewart, W. E., W. D.  Scott,  and S.  E.  Sulkin.  1969.  Relative  sensitivities  of viruses  to different
species of interferon.  J.  Virol. 4: 147.
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almost twice  as long as that  of interferon-sensitive  viruses  like  VSV,  even in
the single-dose cycle.
Dr. Morton Klein (Temple  University  School of Medicine):  We have in-
fected  mice  intranasally  with  a  minimal  infectious  dose  of  influenza  type
A PR8. The mice were treated with cytoxan  at concentrations that completely
inhibited antibody formation but not interferon production.  The lungs of the
mice  were  assayed  for  virus  up  to  15  days  after  infection.  Virus  was  still
present  in  high  titer  (105  infectious  doses)  after  15  days  in  mice  in  which
antibody  was  inhibited  by  cytoxan,  although  it  was  no  longer  detected  in
the  lungs  of  the  untreated  mice.  The  concentration  of  interferon  was  the
same in  the lungs  of both  treated  and control  animals. There was little evi-
dence  of lobar  consolidation  at  these  minimal  infectious  doses  due  to  per-
sistence  of virus  in cytoxan-treated  mice.  The  data  suggest that  persistence
of virus  can  occur in the  absence  of antibody,  but interferon did  not inhibit
the prolonged  persistence  of virus. It is  of interest that prolonged  persistence
of virus was in itself not sufficient  to give  rise to delayed lobar consolidation.
Dr. George Miroff (Union  College):  Dr. Levy, have you tried  this against
spontaneous  tumor?
Dr.  Levy:  We  have  tried  it  against  the  spontaneous  Bitner  tumor-
this is the only spontaneous  tumor we tried it against.
Dr. Miroff: What was the result?
Dr. Levy:  There  was  strong  protection,  depending  on  when  you  gave
the compound.  If you give the compound  early in the course  of the animal's
life,  before  it  really  develops  the  tumor,  particularly  during  the  course  of
pregnancy  and lactation,  the animal  appears not to develop  the tumor later
in life.  If you give the compound  after they have developed tumor, the tumor
appears  to decrease  in size.  We  haven't really yet done much  about the de-
termination,  in the latter case, of increased survival  time.
Dr. Mirof:  In  the  C-57  reticular  cell  glaucoma,  what  is  the  normal
regression  rate,  the spontaneous regression rate of that tumor?
Dr. Levy:  Zero,  or  as  close  to  zero  as you  can  get.  Certainly  well  less
than  1%.
Dr. Fred T.  Valentine  (New  York  University  School  of Medicine):  Dr.
Levy, in your graft versus host studies, have you looked for possible carry-over
of the poly  I:C with the  cells into  the recipient  animal,  and have  you con-
sidered  the possibility  that the observed  effects  could be due to the  influx of
different cell  types into the spleens  of donors treated with poly I: C?
Dr. Levy:  We  thought  of this  possibility,  but we  haven't-the  answer,
strictly  speaking,  is  no.  But we  put the  compound  in  and  then  wait  2  days
before  transferring  the  spleens  from  the  donor  to  the  host.  In  other  tests
where  we've  incubated  the  compound  with  cells,  we  know  that  the  cell
has hydrolyzed  the compound  long before that time has  come. So I  think the
257 258  s INTERFERON  AND  INTERFERON  INDUCERS
likelihood of there being intact poly I :poly  C is extremely  small.  In addition
to which,  of course,  the amount of cells that we transfer  in comparison  with
the amount that is present all together would make an extremely small amount
of material that might be transferred.
Dr. Norbert P. Rapoza (G. D. Searle  & Co., Skokie,  Ill.): Have you done
comparable studies with endotoxin?
Dr. Levy:  I  haven't;  other people  have.  There  are  similarities between
the action  of this  material  and  endotoxin.  The amount  of antitumor effect,
the amount of graft vs.  host effect,  the amount of cellular alterations,  and the
timing  course  appear  to  be  quite different.  People  who  have  worked  with
endotoxin  tell  me that the  pyrogenic  capacity  and  other  actions of poly  I:
poly  C  bear  certain  resemblances  to  those  of endotoxin,  but  they differ  in
many regards.
From the floor: Have you looked at the adenovirus model?
Dr. Miles A.  Galin: No,  we  haven't  looked  at adenovirus  in rabbits  as
of this date.  We anticipate looking particularly at adenovirus  type 8 because
of epidemic keratoconjunctivitis  in humans.